Drugs / Zibotentan
Trials 32
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials · 1 met primary | ||||||
| Phase 1 | NCT07404137 | Feb → Apr 2026 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06715670 | Dec 2024 → Feb 2025 | cirrhosis of liver | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05505162 | Aug 2022 → Jan 2023 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05112419 | Nov → Dec 2021 | impaired renal function disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04991571 | Jul → Oct 2021 | chronic kidney disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00997945 | Oct 2009 → Sep 2010 | high grade malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00709553 | Jul → Aug 2008 | — | AstraZeneca | Completed | Met primary |
| Phase 1 | NCT00713791 | Jun → Aug 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00713336 | Jun → Nov 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00710047 | Jun → Aug 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00672581 | Apr 2008 → Mar 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00314782 | Mar 2006 → Mar 2008 | prostate cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 215 trials · 1 met primary · 3 missed | ||||||
| Phase 2 | NCT06942910 | May 2025 → Sep 2026 overdue | chronic kidney disease | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06269484 | Feb → Dec 2024 | cirrhosis of liver | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT05516498 | Oct 2022 → May 2025 | cirrhosis of liver | AstraZeneca | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05570305 | Oct 2022 → Mar 2025 | chronic kidney disease | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 2 | NCT04724837 | Apr 2021 → Jun 2023 | chronic kidney disease | AstraZeneca | Completed | Met primary |
| Phase 2 | NCT04097314 | Oct 2019 → Jun 2023 | coronary microvascular disorder | NHS Greater Glasgow and Clyde | Completed | Missed primary |
| Phase 2 | NCT02047708 | Oct 2014 → Oct 2017 | chronic kidney disease, systemic sclerosis | University College, London | Completed | No outcome recorded |
| Phase 2 | NCT01205711 | Apr 2010 → Jul 2011 | colorectal cancer | Cardiff University | Completed | No outcome recorded |
| Phase 2 | NCT01119118 | Apr 2010 → Aug 2011 | prostate cancer | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 2 | NCT01000948 | Oct 2009 → Jul 2011 | metastatic prostate carcinoma | Aarhus University Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT00929162 | Jun 2009 → Jun 2011 | — | AstraZeneca | Terminated | Missed primary |
| Phase 2 | NCT00745875 | Aug 2008 → Jan 2010 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00090363 | Jul 2004 → Dec 2008 | prostate cancer | AstraZeneca | Completed | Missed primary |
| Phase 2 | NCT00055471 | Jun 2003 → Oct 2005 | metastatic neoplasm, prostate neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01134497 | ? → Aug 2011 | breast cancer | Cardiff University | Withdrawn | No outcome recorded |
| Phase 34 trials · 1 missed | ||||||
| Phase 3 | NCT06087835 | Nov 2023 → Feb 2027 expected | chronic kidney disease | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00626548 | Jan 2008 → Jan 2011 | prostate cancer | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT00617669 | Jan 2008 → May 2011 | prostate cancer | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT00554229 | Nov 2007 → Jul 2010 | prostate cancer | AstraZeneca | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01168141 | Jul 2009 → Sep 2010 | metastatic prostate carcinoma | The Christie NHS Foundation Trust | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01890135 Comparator | Jun 2013 → Jun 2016 | intermittent vascular claudication, peripheral arterial disease | University of Virginia | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-11-03 | AstraZeneca | Results Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial astrazeneca.com ↗
Combination of zibotentan with dapagliflozin showed statistically significant and clinically meaningful reductions in urinary albumin-to-creatinine ratio (UACR), used to assess albuminuria, at 12 weeks compared with dapagliflozin alone. |
| 2011-02-07 | AstraZeneca | Results AstraZeneca halts phase III trial of ZIBOTENTAN in non-metastatic castrate resistant prostate cancer astrazeneca.com ↗
AstraZeneca today announced that the phase III ENTHUSE Study 15, studying zibotentan monotherapy in patients with non-metastatic castrate resistant prostate cancer (CRPC), will be stopped following the results of an early efficacy review by the Independent Data Monitoring Committee (IDMC). |
| 2010-09-27 | AstraZeneca | Results Results of Zibotentan Phase III trial in castration resistant prostate cancer astrazeneca.com ↗
AstraZeneca today announced that a study evaluating zibotentan for the treatment of men with metastatic castration resistant prostate cancer (CRPC) did not show a significant improvement in the primary endpoint of overall survival (OS). |
All press releases naming this drug 3 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zibotentan | “Patients with prostate cancer with known osseous metastases were treated with zibotentan (ZD4054) and imaged with combined dynamic NaF/FDG PET/CT before therapy (baseline),...” PMID 25128349 ↗ Jul 201417“ZD4054 (Zibotentan) in patients with hormone resistant prostate cancer and bone metastases.” NCT00554229 ↗ |
| Known as | ZD4054 | “Zibotentan (ZD4054) is an endothelin receptor A (ETA) blocker that undergone extensive human testing and has been shown to be safe in several patient population.” NCT01890135 ↗18“Zibotentan (ZD4054) is an oral, specific ETA-receptor antagonist with demonstrated antitumour activity in xenograft models of human ovarian cancer.” PMID 23234805 ↗ Dec 2012 |
| Action | Inhibit | “the specific ETAR antagonist ZD4054” PMID 19042080 ↗ Nov 20081“Endothelin receptor ET-A antagonist” CHEMBL1628688 ↗ |
| Modality | Small molecule | — CHEMBL1628688 ↗ |
| Route | Oral | “Given Orally Once Daily” NCT00055471 ↗ |
| Target | EDNRA | “Endothelin receptor ET-A antagonist” CHEMBL1628688 ↗ |